(AP Photo/Hans Pennink, File)
美國國立衛生研究院（NIH）與莫德納（Moderna）的COVID-19疫苗臨床試驗中期結果前景良好: 獨立的數據和安全監控委員會（DSMB）負責監督研究性COVID-19疫苗mRNA-1273的三期試驗，該委員會於2020年11月15日審查了試驗數據，並與試驗監督小組分享了其中期分析。對數據的這一中期審查表明該疫苗在預防成人人群中有症狀的COVID-19方面是安全有效的。DSMB報告稱，這一候選疫苗安全且耐受性良好，同時指出疫苗有效率為94.5％。
在這項結果公布前，輝瑞（Pfizer）和BioNTech於11月9日宣布了對一種基於mRNA的Covid-19疫苗的早期分析，該疫苗在先前沒有感染Covid-19的參與者中顯示出90％以上的預防功效。莫德納和輝瑞是美國公司，BioNTech是德國公司。
更多信息：https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine?utm_source=dlvr.it&utm_medium=twitter
Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine: An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 15, 2020. This interim review of the data suggests that the vaccine is safe and effective at preventing symptomatic COVID-19 in adults. The DSMB reported that the candidate was safe and well-tolerated and noted a vaccine efficacy rate of 94.5%. This result follows an announcement on Nov. 9 of early analysis of an mRNA-based Covid-19 vaccine from Pfizer and BioNTech which showed 90+% efficacy in preventing Covid-19 in participants without prior infection. Moderna and Pfizer are American companies, while BioNTech is a German company.
More info: https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine?utm_source=dlvr.it&utm_medium=twitter